Trial Profile
Phase I trial of the DNA hypomethylating agent decitabine (5-Aza-2'-deoxycytidine) in combination with epirubicin both given intravenously to patients with advanced solid tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2005
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Epirubicin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 03 Aug 2005 New trial record.